Johnson & Johnson: A Resilient Healthcare Giant

# Johnson & Johnson Stock Analysis: 30% YTD Growth & Strong Analyst Outlook Explore Johnson & Johnson's impressive stock performance in this podcast episode, where we analyze the healthcare giant's 30% year-to-date growth from $145 to approximately $190 per share. Learn why analysts maintain a "moderate buy" consensus with price targets up to $215, including recent upgrades from major institutions like Bank of America and Royal Bank of Canada. We break down J&J's solid Q2 results with $2.26 EPS and $24 billion revenue, plus examine its attractive 2.8% dividend yield supported by a 27% net margin and 30%+ ROE. Discover why despite recent insider sales, high institutional ownership near 70% signals continued confidence in this healthcare stalwart. Perfect for investors seeking insights on low-volatility, dividend-paying blue chips with strong fundamentals and global market presence. For more http://www.quietplease.ai Stock up on these deals https://amzn.to/3QFpYIX This content was created in partnership and with the help of Artificial Intelligence AI.